With a share just short of 30%, CSL Behring emerged as the dominant
player in the global plasma protein therapeutics market in 2015, says
Transparency Market Research (TMR) in a new study. The company offers
a wide range of products that have broad applications in critical
care, immunology, wound healing, and coagulation. Additionally, CSL
Behring capitalizes on its considerable geographical presence. These
factors are aiding the growth witnessed by the company in the last
few years.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10424
Other prominent players in the market include Kamada, Octapharma
Inc., Biotest Pharmaceuticls, and Grifol. Of these, Grifol led the
plasma protein therapeutics market in the Alpha 1 Anti tripsin and
intravenous immunoglobulin (IVIG) segments in 2015. TMR says that CSL
Behring, Grifols, Baxalta, and Octapharma together accounted for
approximately 82.6% of the global plasma protein therapeutics market.
“The increasing use of immunoglobulins in the treatment of primary
immunodeficiency has been spurring the sales of plasma protein
therapeutics,” said a lead analyst at TMR. “Besides this, the
rising use human albumins in the treatment of blood loss, shocks, and
burns and as a drug formulation agent is also fuelling the
opportunities for the plasma protein therapeutics market,” he
added. The demand for plasma protein therapeutics is also expected to
rise due to the increasing development of new indications, innovation
of solutions for safe and efficient plasma collection, the advent of
novel plasma-derived therapies, and better access to medicines in
developing countries.
On the flip side, the implementation of stringent regulatory policies
and issues pertaining to reimbursements are likely inhibit the
market’s trajectory. The existing complexity in biologics
manufacturing is also expected to create bottlenecks for the market.
Nevertheless, the rising healthcare in the emerging
economies will boost prospects for the market in the forthcoming
years.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=10424
Regionally, North America held the dominant share of 40.7% in the
global plasma protein therapeutics market in 2015. Intravenous
immunoglobulin (IVIG) has emerged as the leading segment in the
regional market primarily due to its rising usage in new researches
and new indications. The increasing geriatric population, also boosts
demand from IVIG from the North America market.
During the same time, Europe held the second largest share in the
global plasma protein therapeutics market. The amount of plasma
collected and processed in Europe has doubled itself since the last
decade. This has augured well for the prospects of plasma protein
therapeutics market in Europe. Some of the most lucrative markets for
plasma protein therapeutics in Europe include Germany, Italy,
Switzerland, France, Spain, Sweden, and the U.K.
However, Asia Pacific has been exhibiting the most attractive
opportunities for the global plasma protein therapeutics market. The
region is expected to demonstrate the highest CAGR of all between
2016 and 2024. TMR projects the regional market to rise at a CAGR of
8.1% during the forecast period.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10424
By product, immunoglobulin emerged dominant, holding a share of 40%
in the plasma protein therapeutics market in 2015. The demand for
immunoglobulin has been increasing in response to the surging
production of plasma-based drugs. Since these drugs are found quite
efficient in the treatment of primary immunodeficiency diseases,
demand from the product segment is likely to continue increasing at a
robust pace through the forecast period.
By application, use of plasma protein therapeutics is expected to
rise in the treatment of both primary and secondary immunodeficiency
disorders.
Transparency Market Research pegs the global plasma protein
therapeutics market to reach US$31.8 bn by the end of 2024, from a
valuation of US$18.5 bn in 2015. The market is thus projected to
exhibit a CAGR of 7.0% between 2016 and 2024.
Report Overview @
https://www.transparencymarketresearch.com/plasma-protein-therapeutics-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment